JanOne to present prior Phase II data on diabetic neuropathy

JanOne announced that it will present prior data on Jan101’s randomized double blind placebo-controlled trial in diabetic neuropathy patients. Dr. Amol Soin, Chief Medical Officer of JanOne, will present the results and noted that “This data shows that Jan101 may provide a non-opioid solution to treat diabetic neuropathy pain, but what was also quite exciting was that we saw improvement in nerve conduction velocity which may indicate that Jan101 may actually help the disease process by potentially improving nerve function. If proven further, this could be game changing for patients.”